Atossa Therapeutics, INC. Stock: price and directors' dealings · United States · SEC (Form 4)

About Atossa Therapeutics, INC.

Atossa Therapeutics, Inc. (ticker: ATOS) is a U.S.-listed clinical-stage biopharmaceutical company quoted on NASDAQ in the United States. Headquartered in Seattle, Washington, Atossa was incorporated in April 2009 and originally focused on breast-health devices and diagnostic concepts before evolving into a drug-development company centered on oncology. For international investors, this is best viewed as a development-stage biotech rather than a revenue-generating pharmaceutical platform, which means valuation is primarily driven by clinical data, regulatory progress, intellectual property, and financing capacity. The company’s lead asset is oral (Z)-endoxifen, the active metabolite of tamoxifen. Atossa is developing this proprietary compound across multiple breast-cancer settings, including risk reduction, neoadjuvant treatment in premenopausal women with ER+/HER2- disease, and a metastatic breast-cancer strategy that management has highlighted as potentially offering a more efficient regulatory path. The company has also expanded the potential utility of (Z)-endoxifen beyond oncology, notably into Duchenne muscular dystrophy, where it received meaningful FDA designations in late 2025 and early 2026. That broadens the narrative from a single oncology program to a potential platform asset, although the scientific and regulatory risk remains high. Atossa’s competitive position is that of a niche, highly focused small-cap biotech operating in one of the most crowded therapeutic areas: breast cancer. Its differentiation is built around a proprietary molecule, a concentration on hormone-receptor-positive disease, biomarker-oriented development, and an attempt to streamline the path to approval through targeted clinical and regulatory interactions. In practice, Atossa competes indirectly with major oncology franchises from large-cap pharma as well as many other specialty biotechs pursuing endocrine, targeted, or biomarker-driven therapies. Because it lacks marketed products, the investment case depends on whether its clinical readouts can validate a distinct efficacy and safety profile. Geographically, the business is centered in the United States, with Seattle serving as the corporate base, while its public market listing is NASDAQ in the United States. Recent milestones have included FDA discussions on the development strategy for (Z)-endoxifen, protocol refinement for the EVANGELINE study, and the receipt of FDA Rare Pediatric Disease and Orphan Drug designations for Duchenne muscular dystrophy. These events suggest an active regulatory agenda and a management team seeking multiple value-inflection points. Overall, Atossa remains a high-risk, high-upside clinical-stage oncology company whose near- to medium-term performance will be driven by trial execution and regulatory milestones rather than commercial sales.